Advertisement
COO vs RMD
Which Stock Would AI Choose? The Cooper Companies (COO) vs. ResMed (RMD) Stock Comparison
Key Takeaways
- The Cooper Companies (COO) and ResMed (RMD) both operate in the medical devices sector but target distinct areas: vision care and women’s health for COO, and sleep-disordered breathing and respiratory care for RMD.
- Recent market activity shows COO shares facing steeper declines compared to RMD, with broader pressure noted over the past month amid sector volatility.
- RMD reported double-digit revenue growth in its most recent fiscal quarter and announced a strategic divestiture to sharpen focus on core operations.
- COO delivered organic revenue growth in its latest reported quarter but recorded a notable litigation-related charge impacting earnings.
- Sector exposure differs in growth drivers, with RMD benefiting from ongoing demand in respiratory health solutions and COO tied to vision and surgical products.
- Relative positioning reflects trade-offs in stability, with RMD showing stronger recent momentum in earnings beats while both face typical healthcare regulatory and competitive risks.
Introduction
Investors and traders evaluating healthcare equities often compare specialized medical device companies to assess relative performance, sector positioning, and resilience in varying market conditions. The Cooper Companies (COO) and ResMed (RMD) represent two such names with focused portfolios in vision care and respiratory health, respectively. This comparison appeals to those seeking insights into how these stocks have navigated recent market activity, including earnings trends and operational developments, to inform portfolio allocation decisions within the broader healthcare space.
COO Overview and Recent Performance
The Cooper Companies (COO) is a global medical device firm with primary operations in vision care products, including contact lenses, as well as women’s health and surgical solutions. In recent market activity, shares have experienced downward pressure, contributing to underperformance relative to broader indices over the past several weeks. The company’s fiscal second quarter results, released in early June 2026, showed revenue of $1.082 billion, reflecting 8% year-over-year growth or 5% on an organic basis. However, GAAP diluted earnings per share turned negative at $(0.40) due in part to a litigation-related charge tied to a prior product recall. Organic growth in core segments provided some support to sentiment, though overall positioning reflected caution amid these one-time factors.
RMD Overview and Recent Performance
ResMed (RMD) develops and markets devices and solutions for sleep-disordered breathing and other respiratory conditions. Recent market activity has been influenced by the company’s fiscal third quarter results from April 2026, which delivered revenue of $1.4 billion, up 11% year-over-year, alongside non-GAAP earnings per share of $2.86 that exceeded consensus estimates. In early July 2026, ResMed announced an agreement to sell its MatrixCare business for $490 million, a move intended to concentrate resources on its primary sleep and respiratory platforms. Stock performance over recent weeks has shown relative resilience compared to some peers, supported by consistent demand and operational execution, though broader sector dynamics have contributed to volatility.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from its extensive library of hundreds of automated strategies. These bots cover thousands of tickers across diverse trading styles, timeframes, performance metrics, and risk profiles, with only the most suitable for prevailing conditions featured in the trending list. Available statistics often include ranges for win rates, average returns per trade, and drawdown measures that vary by bot, allowing users to evaluate alignment with specific market environments. The platform emphasizes factual differentiation in strategies rather than uniform outcomes. Review the full selection on the Trending AI Robots page for current options.
Head-to-Head Comparison
In business models, The Cooper Companies (COO) emphasizes vision correction and women’s health devices with exposure to elective procedures, while ResMed (RMD) centers on chronic respiratory care with recurring revenue elements from masks and accessories. Growth drivers diverge accordingly: COO benefits from contact lens adoption trends, whereas RMD leverages rising awareness of sleep apnea solutions. Recent momentum favors RMD following its earnings beat and divestiture announcement, contrasting with COO’s litigation impact on reported earnings. Risk factors include regulatory scrutiny and competition for both, though RMD’s focus on essential therapies may offer relative stability. Sector exposure places both in healthcare but with limited direct overlap, creating trade-offs in cyclical sensitivity versus steady demand patterns. Market sentiment reflects these contrasts, with observable differences in price resilience over recent periods.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, operational catalysts like the MatrixCare divestiture, and relative price behavior in recent market activity, Tickeron’s AI models indicate a probabilistic preference for ResMed (RMD) in current positioning. Trend consistency and growth metrics appear more supportive for RMD compared to the litigation-influenced results at The Cooper Companies (COO), though both remain subject to broader healthcare dynamics and no outcome is assured.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Buy and RMD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileRMD’s FA Score has 1 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- RMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 4 TA indicator(s) are bullish while RMD’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 4 bullish, 4 bearish.
- RMD’s TA Score: 5 bullish, 5 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а +2.61% price change this week, while RMD (@Pharmaceuticals: Other) price change was +5.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.26%. For the same industry, the average monthly price growth was +8.63%, and the average quarterly price growth was +6.97%.
Reported Earning Dates
COO is expected to report earnings on Sep 09, 2026.
RMD is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.26% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| COO | RMD | COO / RMD | |
| Capitalization | 14.9B | 32.4B | 46% |
| EBITDA | 890M | 2.18B | 41% |
| Gain YTD | -7.064 | -6.319 | 112% |
| P/E Ratio | 64.55 | 21.52 | 300% |
| Revenue | 4.23B | 5.54B | 76% |
| Total Cash | 139M | 1.66B | 8% |
| Total Debt | 2.46B | 843M | 292% |
COO | RMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 39 | |
PRICE GROWTH RATING 1..100 | 45 | 49 | |
P/E GROWTH RATING 1..100 | 10 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMD's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for COO (67). This means that RMD’s stock grew somewhat faster than COO’s over the last 12 months.
RMD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that RMD’s stock grew similarly to COO’s over the last 12 months.
RMD's SMR Rating (39) in the Medical Specialties industry is somewhat better than the same rating for COO (89). This means that RMD’s stock grew somewhat faster than COO’s over the last 12 months.
COO's Price Growth Rating (45) in the Medical Specialties industry is in the same range as RMD (49). This means that COO’s stock grew similarly to RMD’s over the last 12 months.
COO's P/E Growth Rating (10) in the Medical Specialties industry is significantly better than the same rating for RMD (81). This means that COO’s stock grew significantly faster than RMD’s over the last 12 months.
| COO | RMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 47% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 55% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 59% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 58% |
| Advances ODDS (%) | 4 days ago 55% | 2 days ago 56% |
| Declines ODDS (%) | 1 day ago 60% | 8 days ago 60% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 60% |
Advertisement
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
| Ticker / NAME | Correlation To COO | 1D Price Change % | ||
|---|---|---|---|---|
| COO | 100% | -0.56% | ||
| BDX - COO | 56% Loosely correlated | +0.79% | ||
| A - COO | 50% Loosely correlated | -0.51% | ||
| MMSI - COO | 46% Loosely correlated | +0.29% | ||
| DHR - COO | 46% Loosely correlated | -0.71% | ||
| ICUI - COO | 44% Loosely correlated | -0.07% | ||
More | ||||
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -1.01% | ||
| COO - RMD | 50% Loosely correlated | -0.56% | ||
| BAX - RMD | 47% Loosely correlated | -1.18% | ||
| SOLV - RMD | 46% Loosely correlated | +2.46% | ||
| BDX - RMD | 46% Loosely correlated | +0.79% | ||
| ISRG - RMD | 43% Loosely correlated | -1.68% | ||
More | ||||